Catalent Pharma Solutions, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2013. For the quarter, net revenue was $447.0 million against $441.3 million for the same period a year ago. Operating earnings was $47.9 million against $52.8 million for the same period a year ago. Loss from continuing operations before income taxes was $14.0 million against earnings $5.5 million for the same period a year ago. Loss from continuing operations was $13.9 million against $2.7 million for the same period a year ago. Net loss attributable to catalent was $18.8 million against $9.2 million for the same period a year ago. EBITDA from continuing operations was $78.7 million against $87.2 million for the same period a year ago. Adjusted EBITDA was $108.6 million against $100.6 million for the same period a year ago. For the nine months, net revenue was $1,295.1 million against $1,216.5 million for the same period a year ago. Operating earnings were $125.9 million against $150.1 million for the same period a year ago. Loss from continuing operations before income taxes was $55.1 million against earnings from continuing operations before income taxes of $22.0 million for the same period a year ago. Loss from continuing operations was $61.0 million against earnings from continuing operations of $3.0 million for the same period a year ago. Net loss attributable to catalent was $65.9 million against $2.2 million for the same period a year ago. EBITDA from continuing operations was $220.5 million against $244.8 million for the same period a year ago. Net cash provided by operating activities from continuing operations was $84.4 million against $81.9 million for the same period a year ago. Acquisition of property and equipment and other productive assets was $84.8 million against $67.6 million for the same period a year ago.

Catalent Pharma Solutions, Inc., Q3 2013 Earnings Call, May 10, 2013

On April 29, 2013, Catalent Pharma Solutions, Inc. (the Company), the Company's subsidiaries that are guarantors thereunder, certain lenders, and Morgan Stanley Senior Funding, Inc., as the administrative agent, entered into a Senior Unsecured Term Loan Credit Agreement, in order to borrow an aggregate principal amount of $275,000,000 of unsecured term loans. The proceeds of the Unsecured Loans will be used to redeem all of the Company's outstanding 9.5%/10.25 % Senior PIK-Election Notes due 2015 at par plus accrued and unpaid interest to the date of redemption. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Credit Agreement.